• FPH1 (BRD-6125) Hepatocyte Workflow Guide

  2026-08-28

  FPH1 (BRD-6125) supports a function-first strategy for expanding primary human hepatocytes and improving iPSC-derived hepatocyte-like cells. This guide translates the product profile into practical dosing, assay design, troubleshooting, and a carefully bounded connection to light-regulated gene-expression research.

• mCherry mRNA for Nanoparticle Assay Design

  2026-08-28

  Learn how mCherry mRNA can function as more than a fluorescent reporter: it can help separate nanoparticle loading, cellular uptake, translation, and transcript persistence. This practical framework highlights how EZ Cap™ mCherry mRNA supports reproducible delivery and formulation decisions.

• Meropenem Trihydrate in Resistance Research

  2026-08-27

  Learn how Meropenem trihydrate supports reproducible susceptibility testing, resistance phenotyping, and metabolomics-informed assay design. This workflow-focused guide connects a broad-spectrum carbapenem antibiotic to practical controls, sample-handling decisions, and troubleshooting for bacterial infection treatment research.

• N-MYC–eIF4G1 Axis in inv(16) AML

  2026-08-27

  A 2024 Science Advances study identifies an essential MYCN enhancer and establishes the N-MYC/eIF4G1 pathway as a survival circuit in inv(16) acute myeloid leukemia. Its combined pharmacologic, transcriptional, functional, and patient-derived xenograft evidence clarifies how CBFβ-SMMHC-associated signaling sustains leukemia and suggests measurable endpoints for acute myeloid leukemia research.

• Cas9 mRNA–gRNA Delivery for LGMN Editing

  2026-08-26

  This Scientific Reports study developed a lipid nanoparticle strategy for co-delivering Cas9 mRNA and guide RNA to edit the metastasis-associated LGMN gene in breast cancer models. Its findings connect transient RNA-based genome editing with impaired lysosomal function and reduced cancer-cell migration and invasion, while also identifying practical considerations for guide-RNA and Cas9 mRNA production.

• Epacadostat (INCB024360) in Whole-Blood IDO1 Assays

  2026-08-26

  Epacadostat (INCB024360) converts standardized whole-blood stimulation into a practical model for linking IDO1 activity with cytokine and tryptophan-catabolism changes. This guide covers assay setup, checkpoint-inhibitor combination testing, dose selection, and troubleshooting while separating validated product properties from workflow recommendations.

• JXY, TLR4, and Macrophage Polarization in CAC

  2026-08-25

  The reference study shows that Jiedu Xiaozheng Yin suppresses colitis-associated colorectal cancer in mice while shifting intestinal macrophages toward an M1-like phenotype through TLR4-associated signaling. Its integrated in vivo, cellular, transcriptional, and pharmacological design connects tumor burden with immune-state remodeling and provides a useful framework for investigating inflammation-driven colorectal cancer.

• Alternariol (AOH) in Fibrosis Research

  2026-08-25

  Alternariol (AOH) enables controlled studies of hepatic stellate cell activation, CYP1A1/CYP1A2 metabolism, apoptosis, and foodborne toxin biology. This workflow-focused guide shows how to prepare, dose, compare, and troubleshoot AOH experiments while separating product handling recommendations from findings reported in the reference study.

• Inside-Out Engineering of RNA Nanoparticles

  2026-08-24

  The ACS Nano study develops a systematic framework for engineering ternary polyelectrolyte nanoparticles by tuning PEGylated polyanion chemistry around self-amplifying RNA polyplexes. Combining stability screening, neutron scattering, cell studies, and molecular dynamics, the authors show that a moderate balance of hydrophobicity and charge density can couple extracellular stability with intracellular RNA release.

• Cy5-UTP: Mechanism, RNA Labeling & Workflow

  2026-08-24

  Cy5-UTP, also called Cyanine 5-uridine triphosphate, is a fluorescent UTP analog for T7 polymerase–mediated RNA probe synthesis. Its documented 650/670 nm excitation and emission maxima support direct fluorescence detection in FISH, multicolor analysis, and dual-color expression arrays.

• Licoricidin in HCC: PI3K/AKT, Growth, and Metastasis

  2026-08-23

  A February 2026 study reports that the licorice-derived prenylated isoflavone licoricidin inhibits hepatocellular carcinoma growth and metastatic behavior in cell and mouse models. Its value lies in connecting S-phase arrest, apoptosis, epithelial–mesenchymal transition suppression, and reduced PI3K/AKT signaling, while also highlighting the need for stronger target-validation and translational studies.

• Intravesical p21 mRNA-LNP Therapy in Bladder Cancer

  2026-08-22

  This FASEB Journal study develops chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. The approach restored nuclear p21, suppressed tumor-associated cell-cycle activity, and reduced orthotopic tumor growth while limiting systemic distribution in mice.

• OTUD3–SLC7A11 Axis in Sunitinib Resistance

  2026-08-22

  The reference study identifies OTUD3-mediated stabilization of SLC7A11 as a mechanism that protects clear cell renal cell carcinoma from sunitinib-induced ferroptosis. Its findings connect deubiquitination, cystine utilization, glutathione-dependent redox control, lipid peroxidation, and therapeutic resistance, while suggesting that OTUD3 is a potential sensitization target.

• Paroxetine Mesylate: From SERT to CRC Assays

  2026-08-21

  Paroxetine Mesylate is more than a Selective serotonin reuptake inhibitor: it is a valuable probe for connecting SERT pharmacology with MET–ERBB3 signaling in colorectal cancer models. This article translates the key evidence into practical assay-design decisions while separating established findings from exploratory interpretation.

• Hoechst 33342/PI Double Staining Kit Workflow

  2026-08-20

  Build a rapid fluorescent apoptosis assay that separates chromatin condensation from loss of membrane integrity in one microscopy workflow. The kit is especially useful for testing treatment response, including syringin–sunitinib combinations in renal cell carcinoma models, while disciplined controls and image analysis improve interpretation.

8008 records 1/534 page Next 12345 下5页 Last page